By pairing a Ciara remix with a twice-yearly dosing schedule, Gilead’s campaign aims to cut through longstanding stigma and close the gap in PrEP uptake.

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Please provide your email address to receive an email when new articles are posted on . Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

According to ABC News' latest report, almost 38,000 Americans are diagnosed with HIV (human immunodeficiency virus) every year. There are already treatments to prevent HIV infection. In 2012, the Food ...

Please provide your email address to receive an email when new articles are posted on . Replacing daily oral PrEP with long-acting injectable PrEP could modestly decrease HIV incidence among men who ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

ViiV expects injectables to steal significant market share from oral treatments, such as Gilead’s Biktarvy, which currently dominate the HIV field. In the prevention arena, the company is awaiting an ...